Try our Advanced Search for more refined results
Track this case
IPR2019-00688
IPR
Final Written Decision
Nalox-1 Pharmaceuticals, LLC
Opiant Pharmaceuticals, Inc.
9468747
1600
Filed: February 19, 2019 00:00
The Patent Trial and Appeal Board has refused to invalidate three different patents covering Adapt Pharma Ltd.'s opioid overdose treatment Narcan, two of which had a different fate in district court.
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
TRY LAW360 FREE FOR SEVEN DAYS
Already a subscriber? Click here to login
Email (NOTE: Free email domains not supported)
First Name
Last Name
Job Title
PLEASE NOTE: A verification email will be sent to your address before you can access your trial.
Password (at least 8 characters required)
Confirm Password
Law360 may contact you in your professional capacity with information about our other products, services and events that we believe may be of interest.You’ll be able to update your communication preferences via the unsubscribe link provided within our communications.We take your privacy seriously. Please see our Privacy Policy.